Kusuma K

Biotechnological products have transformed modern medicine by providing targeted and innovative therapies, including recombinant proteins, monoclonal antibodies, gene therapies, and vaccines, forming the foundation of precision medicine. However, their biological complexity and structural variability necessitate stringent regulatory oversight to ensure safety, efficacy, and quality. This study presents a comparative analysis of regulatory frameworks governing biotechnological products in India and the United States. In India, the Central Drugs Standard Control Organization (CDSCO) serves as the apex regulatory authority, implementing guidelines under the Drugs and Cosmetics Act of 1940. It mandates rigorous preclinical evaluations, phased clinical trials, adherence to Good Manufacturing Practices (GMP), and robust post-marketing surveillance to ensure product safety and therapeutic benefit. Conversely, the United States Food and Drug Administration (US FDA) regulates biotechnological products under the Public Health Service (PHS) Act and the Food, Drug, and Cosmetic (FD&C) Act. A distinctive feature of the US system is the Biologics License Application (BLA), which requires extensive clinical trials, comprehensive pharmacovigilance, and stringent GMP compliance, reflecting a strong emphasis on scientific validation and patient safety. The comparative analysis highlights key differences in approval timelines, regulatory pathways, clinical data requirements, and pharmacovigilance mechanisms. While CDSCO focuses on accessibility and affordability within India, the US FDA prioritizes exhaustive scientific evaluation and global standardization. Understanding these regulatory nuances is essential for pharmaceutical companies to streamline product development, ensure compliance, and foster public trust. This study underscores the need for harmonization and mutual recognition of standards to accelerate global patient access to life-saving biotechnological therapies.

An accurate, simple and precise RP-HPLC method for the simultaneous estimation sulfadiazine and trimethoprim in pharmaceutical formulations was developed and validated. Chromatographic separation of two drugs was achieved on PEAK 7000 isocratic HPLC with rheodyne manual sample injector by using the mobile phase consisting of methanol, water and aceticacid in the ratio 70:25:05 (v/v/v) at a flow rate of 1mL/min and the wavelength of detection was at 237 nm. The retention time for sulfadiazine and trimethoprim were found to be 4.24 and 7.25 min respectively. The linearity of the method was tested over a concentration range of 41-287 µg/mL for sulfadiazine and 9-63 µg/mL for trimethoprim and the correlation coefficient was 0.999 for sulfadiazine and 0.998 for trimethoprim which is almost equal to 1. The limit of quantification was 3.5 μg/mL for sulfadiazine and 1 μg/mL for trimethoprim and the limit of detection was 1 μg/mL for sulfadiazine and 0.3 μg/mL for trimethoprim. The percentage recoveries were ranged from 98.64-101.64 for sulfadiazine and 98.56-100.86 for trimethoprim.